Evidence map›Paper›PMID 39377592›Full record

ArticleCancer medicine2024

Evaluation of the safety of PD-1/PD-L1 inhibitors for immunotherapy in patients with malignant tumors after COVID-19 infection: A single-center cohort study.

Kaili Liao, Jinting Cheng, Yujie Hu, Beining Zhang, Peng Huang, Jie Liu, Wenyige Zhang, Huan Hu, Xinyi Bai, Yihui Qian and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kaili LiaoDepartment of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Jinting ChengSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yujie HuThe 1st Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.
Beining ZhangQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.
Peng HuangDepartment of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Jie LiuSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
Wenyige ZhangQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.
Huan HuSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
Xinyi BaiSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yihui QianThe 2nd Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.
Daixin GuoSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
Kun AiQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuchen ZhuThe 1st Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.
Long HuangDepartment of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0002-5372-071X

Funding

National Natural Science Foundation of China 81960468National Natural Science Foundation of China 81960571
6 · The paper itself

Abstract

introductionAn increasing body of evidence suggests a close association between COVID-19 infection and the safety of PD-1/PD-L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. MATERIAL AND

methodsWe conducted a retrospective analysis of cancer patients who received PD-1/PD-L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune-related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter-subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher's exact, chi-squared, and Mann-Whitney U-tests.

resultThe results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD-1/PD-L1 inhibitors, and alterations in hepatic and renal function (p > 0.05).

conclusionOur findings suggest that infection with COVID-19 does not significantly impact the safety of PD-1/PD-L1 inhibitors in cancer patients. Most cancer patients used PD-1/PD-L1 inhibitors during COVID-19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.

Indexed as

COVID-19Immune Checkpoint InhibitorsNeoplasmsSARS-CoV-2AdultAgedAged, 80 and overB7-H1 AntigenFemaleHumansImmunotherapyMaleMiddle AgedProgrammed Cell Death 1 ReceptorRetrospective StudiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorcancerCOVID‐19 infectionimmune‐related adverse eventsPD‐1/PD‐L1 inhibitorpropensity score matching

Identifiers

PMID39377592
PMCPMC11459677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.